Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...

On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...

The Trump administration has started quietly rehiring some of the U.S. Food and Drug Administration employees it fired last week, according to nine agency sources, shortly after letting them go in a ...